| 26 |
Guideline [Chronically active Crohn's disease] 2003
Hoffmann J, Zeitz M, Anonymous00107. · Klinik für Gastroenterologie, Universitätsklinikum Benjamin Franklin, Berlin. · Z Gastroenterol. · Pubmed #12541171 No free full text.
This publication has no abstract.
|
| 27 |
Guideline [Acute episode] 2003
Schölmerich J, Anonymous00106. · Klinik für innere Medizin, Universitätsklinikum Regensburg. · Z Gastroenterol. · Pubmed #12541170 No free full text.
This publication has no abstract.
|
| 28 |
Guideline [Pathologic diagnostics] 2003
von Herbay A, Anonymous00105. · Pathologisches Institut, Universitätsklinikum Heidelberg. · Z Gastroenterol. · Pubmed #12541169 No free full text.
This publication has no abstract.
|
| 29 |
Guideline [Clinical diagnostics, classification] 2003
Schreiber S, Fölsch UR, Anonymous00104. · Medizinische Universitätsklinik, Kiel. · Z Gastroenterol. · Pubmed #12541168 No free full text.
This publication has no abstract.
|
| 30 |
Guideline [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis] 2003
Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA, Anonymous00002. · Servicio de Digestivo. Hospital Son Dureta. Palma de Mallorca. España. · Gastroenterol Hepatol. · Pubmed #12525326 No free full text.
This publication has no abstract.
|
| 31 |
Guideline [Practice guidelines in gastroenterology. Use of anti-TNF agents in inflammatory bowel disease.European guide 2001-2003] 2002
Anonymous77740. · No affiliation provided · Rom J Gastroenterol. · Pubmed #12219731 No free full text.
This publication has no abstract.
|
| 32 |
Guideline [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001] 2002
Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull MA, Anonymous00043. · Hospital Universitari Germans Trías i Pujol, Badalona, Barcelona, Spain. · Gastroenterol Hepatol. · Pubmed #11864540 No free full text.
This publication has no abstract.
|
| 33 |
Guideline Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. free! 2001
Fedorak RN, Anonymous00256. · University of Alberta, Edmonton, Canada. · Can J Gastroenterol. · Pubmed #11429665 links to free full text
This publication has no abstract.
|
| 34 |
Guideline Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. 2001
Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P, Anonymous00293. · Department of Medicine I, University Hospital Kiel, Schittenhelmstrasse 12, 24105 Kiel, Germany. · Int J Colorectal Dis. · Pubmed #11317691 No free full text.
Abstract: The introduction of novel anti-tumor necrosis factor (TNF) agents has not only led to impressive new therapeutic opportunities but also resulted in uncertainty regarding their optimal use and possible side effects. Guidelines are presented here for the use of anti-TNF agents in gastrointestinal disorders. Experts were chosen from different European countries by an algorithm to avoid bias. An expert consensus on guidelines was established using a two-stage procedure of systematic Medline and abstract search for evidence and a qualifying meeting to derive recommendations. Detailed guidelines were developed for the use and the future clinical development of anti-TNF agents in inflammatory bowel disease. Grading of available evidence and grading of recommendations were performed according to AHCPR guidelines. At present infliximab is the only registered agent for Crohn's disease. Infliximab should be always used at a dose of 5 mg/kg. The guidelines define the indications both in refractory and in fistulating disease for the readministration and before surgery. Guidelines for safety and for concomitant treatments are given. Prospects, potential clinical use, and future directions for the clinical development of other anti-TNF agents are detailed. Clinical use of anti-TNF agents will be influenced by a large number of clinical trials being concluded in 2001 and 2002. It is likely that anti-TNF therapies will become an important long-term therapy for a proportion of patients with Crohn's disease. Biological agents will be followed by smaller and more stable, orally available compounds. These guidelines will be succeeded by a formal public consensus in 2002/2003.
|
| 35 |
Guideline Management of Crohn's disease in adults. 2001
Hanauer SB, Sandborn W, Anonymous00243. · University of Chicago Pritzker School of Medicine, Illinois 60637, USA. · Am J Gastroenterol. · Pubmed #11280528 No free full text.
This publication has no abstract.
|
| 36 |
Editorial Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. 2009
Achkar JP, Fiocchi C. · No affiliation provided · Am J Gastroenterol. · Pubmed #19436278 No free full text.
Abstract: The results of recently completed genome-wide association studies have advanced knowledge of inflammatory bowel disease (IBD) genetics, including the identification of over 30 genes or loci associated with Crohn's disease (CD). The possibility of interactions between genes, referred to by the term epistasis, needs to be carefully considered as both genetic and functional studies in IBD move forward. We review a paper in this issue of the Journal that reports evidence of epistasis in CD, and we discuss important issues that arise when trying to determine whether there is indeed interaction between genes and what their potential implications for disease pathogenesis and clinical outcome might be.
|
| 37 |
Editorial Genetics of Crohn's disease. 2008
Agrawal S. · No affiliation provided · Indian J Gastroenterol. · Pubmed #19405253 No free full text.
This publication has no abstract.
|
| 38 |
Editorial [Therapeutic combinations] 2009
Michetti P. · No affiliation provided · Rev Med Suisse. · Pubmed #19271426 No free full text.
This publication has no abstract.
|
| 39 |
Editorial [Adalimumab in Crohn's disease - data from real life] free! 2008
López San Román A, Van Domselaar M, Garrido E. · No affiliation provided · Rev Esp Enferm Dig. · Pubmed #19159169 links to free full text
This publication has no abstract.
|
| 40 |
Editorial [Treatment for intraabdominal abscess in Crohn's disease] free! 2009
Park YS. · No affiliation provided · Korean J Gastroenterol. · Pubmed #19158474 links to free full text
This publication has no abstract.
|
| 41 |
Editorial Crohn disease and autophagy. 2009
Klionsky DJ. · No affiliation provided · Autophagy. · Pubmed #19139633 No free full text.
This publication has no abstract.
|
| 42 |
Editorial Exposed: the genetic underpinnings of ulcerative colitis relative to Crohn's disease. 2009
Brant SR. · No affiliation provided · Gastroenterology. · Pubmed #19121319 No free full text.
This publication has no abstract.
|
| 43 |
Editorial Road most traveled: gut-specific migration signals and leucocyte entry to the intestine. 2008
Grimm MC, Ng WS. · No affiliation provided · J Gastroenterol Hepatol. · Pubmed #19120867 No free full text.
This publication has no abstract.
|
| 44 |
Editorial Using genetic information for the identification, classification and treatment of Crohn's disease: are we there yet? 2008
Weersma RK, Wijmenga C. · No affiliation provided · Expert Rev Gastroenterol Hepatol. · Pubmed #19090731 No free full text.
This publication has no abstract.
|
| 45 |
Editorial [Which place for methotrexate in treatment of luminal Crohn's disease?] 2009
Carbonnel F. · No affiliation provided · Gastroenterol Clin Biol. · Pubmed #19084362 No free full text.
This publication has no abstract.
|
| 46 |
Editorial Crohn's disease: drug therapy or surgery? 2007
Hyman NH. · No affiliation provided · Expert Rev Gastroenterol Hepatol. · Pubmed #19072408 No free full text.
This publication has no abstract.
|
| 47 |
Editorial Boning up: exploring bone structure and strength in children with Crohn's disease. 2009
Gordon CM. · No affiliation provided · Gastroenterology. · Pubmed #19041650 No free full text.
This publication has no abstract.
|
| 48 |
Editorial The growing skeleton is a busy place--can biochemical bone markers keep track of the action? 2008
Rauch F. · No affiliation provided · J Pediatr. · Pubmed #18847616 No free full text.
This publication has no abstract.
|
| 49 |
Editorial Esophageal Crohn disease. 2008
Cichoz-Lach H. · No affiliation provided · South Med J. · Pubmed #18708981 No free full text.
This publication has no abstract.
|
| 50 |
Editorial Mea culpa. 2008
Hanauer SB. · No affiliation provided · Nat Clin Pract Gastroenterol Hepatol. · Pubmed #18670441 No free full text.
This publication has no abstract.
|
Prior · Next |